1. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 62: 2016–2, 1988.
2. 平成 29 年人口動態統計(厚生労働省大臣官房統計情報部編)
3.がん診療連携拠点病院等院内がん登録生存率集計(国立がん研究セ ンターがん情報サービス)
4. 膀胱癌診療ガイドライン 2019 年版(日本泌尿器科学会 編)
5. 腎盂・尿管診療ガイドライン 2014 年版(日本泌尿器科学会 編)
6. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23(21):4602–8, 2005.
7. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 30(6):970–976, 2019.
8. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 376:1015–1026, 2017.
9. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 23(8):1920–28, 2017.
10. Ferrara R, Mezquita L, Texier M,et al. Hyper progressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 4(11):1543–1552, 2018.
11. Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ. Predictive biomarkers for drug response in bladder cancer. Int J Urol. 26(11):1044–1053, 2019.
12. Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 14(11):655–668, 2017.
13. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16(5)275–87, 2016.
14. DNA Sequencing Costs: Data. National Human Genome Research Institute. https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Cos ts-Data
15. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molechlar Oncology. J Mol Diagn. 17(3):251–64, 2015.
16. Kohsaka S, Tatsuno K, Ueno T, et al. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin -fixed paraffin-embedded specimens. Cancer Sci. 110(4):1464–1479, 2019.
17. Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Mol Cancer Ther. 16(6):1010–1020, 2017.
18. Karkera JD, Cardona GM, Bell K, et al. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Mol Cancer Ther. 16(8):1717–1726, 2017.
19. Michaelis C, Ciosk R, Nasmyth K. Cohesins: chromosomal proteins that prevent premature separation of sister chromatids. Cell. 91(1):35–45, 1997.
20. Guacci V, Koshland D, Strunnikov A. A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in S. cerevisiae. Cell. 91(1):47–57, 1997
21. Haarhuis JH, Elbatsh AM, Rowland BD. Cohesin and its regulation: on the logic of X-shaped chromosomes. Dev Cell. 13;31(1):7–18, 2014.
22. Prieto I, Suja JA, Pezzi N,et al. Mammalian STAG3 is a cohesion specific to sister chromatid arms in meiosis I. Nat Cell Biol. 3(8):761–6, 2001.
23. Canudas S, Smith S. Differential regulation of telomere and centromere cohsion by the Scc3 homologues SA1 and SA2, respectively, in human cells. J Cell Biol. 187(2):165–73, 2009.
24. van der Lelij P, Lieb S, Jude J, et al. Synthetic lethality between the cohesion subunits STAG1 and STAG2 in diverse cancer contexts. Elife. 6:e26980, 2017.
25. Viny AD, Bowman RL, Liu Y, et al. Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation. Cell Stem Cell. 25(5):682–696, 2019.
26. Countryman P, Fan Y, Gorthi A, et al. Cohesin SA2 is a sequence-independent DNA-binding protein that recognizes DNA replication and repair intermediates. J Biol Chem. 293(3):1054–1069, 2018.
27. Kleyman M, Kabeche L, Compton DA. STAG2 promotes error correction in mitosis by regulating kinetochore-microtubule attachments. J Cell Sci. 127:4225–33, 2014.
28. Barber TD, McManus K, Yuen KW, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natil Acad Sci USA. 105(9):3443–8, 2008.
29. Rocquain J, Gelsi-Boyer V, Adelaide J, et al. Alteration of cohesion genes in myeloid diseases. Am J Hematol. 85(9):717–9, 2010.
30. Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 333:1039–43, 2011.
31. Kim MS, Kim SS, Je EM, Yoo NJ, Lee SH. Mutational and expressional analyses of STAG2 gene in solid cancers. Neoplasma. 59:524–9, 2012.
32. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 505:495–501, 2014.
33. Tirode F, Surdez D, Ma X,Parker M, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4:1342–53, 2014.
34. Mullenders J, Aranda-Orgilles B, Lhoumaud P, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasm. J Exp Med. 212(11):1833–50, 2015.
35. Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesion complex in myeloid neoplasms. Nat Genet. 45(10):1232–7, 2013.
36. Evers L, Perez-Mancera PA, Lenkiewicz E, et al. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med. 6(1):9, 2014.
37. 日本経済新聞 2016/8/5 「AI、がん治療法助言 白血病のタイプ見 抜く」 https://www.nikkei.com/article/DGXLZO05697850U6A800C1000000/
38. Bailey ML, O'Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol Cancer Ther. 13:724–32, 2014.
39. Matto N, aymes TJ, Kulasekararaj AG, Mian SA, Mufti GJ. Mutations in Cohesin Complex As Potential Targets for therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome. Blood. 126:1221, 2015.
40. McLellan JL, O’Neil NJ, Barrett I, et al. Synthetic lethality of cohesions with PARPs and replication fork mediators. PLoS Genet. 8(3):e1002574, 2012.
41. Liu Y, Xu H, Van der Jeught K, et al. Somatic mutation of the cohesion complex subunit confers therapeutic vulnerabilities in ca ncer. J Clin Invest. 128(7):2951–2965, 2018.
42. Stewart E, Goshorn R, Bradley C, et al. Targeting the DNA repair patheway in Ewing sarcoma. Cell Rep. 9(3):829–41, 2014.
43. Ding S, Diep J, Feng N, et al. STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection. Nat Commun. 9(1):1485, 2018.
44. Shen CH, Kim SH, Trousil S, et al. Loss of cohesion complex components STAG2 or STAG3 confers resistance to BRAF i nhibition in melanoma. Nat Med. 22(9):1056–61, 2016.
45. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45: 1464–9, 2013.
46. Guo G, Sun X, Chen C,et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 45: 1459–63, 2013.
47. Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 45:1428–30, 2013.
48. Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet. 23:1964–74, 2014.
49. Qiao Y, Zhu X, Li A, Yang S, Zhang J. Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer. Tumour Biol. 37:10279–86, 2016.
50. Han Y, Zheng Q, Tian Y, Ji Z, Ye H. Identification of a ni ne-gene panel as a prognostic indicator for recurrence with muscle -invasive bladder cancer. J Surg Oncol. 119(8):1145–1154, 2019.
51. Lelo A, Prip F, Harris BT, et al. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res. 24(17):4145–4153, 2018.
52. Sfakianos JP, Cha EK, Iyer G, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 68:970–7, 2015.
53. Li Q, Bagrodia A, Cha EK, Coleman JA. Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. Curr Urol Rep. 17(2):12, 2016.
54. Li X, Zhang TW, Tang JL, et al. Loss of STAG2 causes aneuploidy in normal human bladder cells. Genet Mol Res. 14:2638–46, 2015.
55. Daniloski Z, Smith S. Loss of Tumor Suppressor STAG2 Promotes Telomere Recombination and Extends the Replicative Lifespan of Normal Human Cells. Cancer Res. 77(20):5530–5542, 2017.
56. Wang H, Zhong J, Wu C, et al. Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells. Oncol Rep. 38(2):917–925, 2017.
57. Liu KX, Lamba N, Hwang WL, et al. Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 125(8):1357–1364., 2019.
58. Zhang Y, Song J, Shi Q, et al. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view. Jpn J Clin Oncol. 49(7):604–613, 2019.
59. Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesion-mutant cancers. Nat Commun. 10(1):1686, 2019.
60. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 70:106–19, 2016.
61. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoconal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31(1):13–20, 1983.
62. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer. 88:2598–605, 2000.
63. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–5, 1984.
64. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder; clinical significance and comparison with other prognostic factors. Cancer. 88:2598–605, 2000.
65. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 163:758–60, 2000.
66. Curtin K, Slattery ML, Holubkov R, et al. p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol. 12(4):380–6, 2004.
67. Fromont G, Roupret M, Amira N, et al. Tissue microarry analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 48:764–70, 2005.
68. Ando K, Oki E, Saeki H, et al. Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med. 4(1):75–83, 2015.
69. Köbel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcionomas. J Pathol. 222(2): 191–8, 2010.
70. Habuchi T, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst. 86(17):1331–5, 1994.
71. Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 86(17):1325–30, 1994.
72. Earl J, Rico D, Carrillo-de-Santa-Pau E, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics. 22;16:403, 2015.
73. Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D. Systematic Review: Charasteristics and Preclinical Uses of Bladder Cancer Cell Lines. Bladder Cancer. 4(2):169–183, 2018.
74. Tsuruta F, Takebe A, Haratake K, et al. SCFFbl12 Increases p12Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis. Mol Cell Biol. 36(16):2182–94, 2016.
75. Inamura K. Bladder Cancer: New Insights into its Molecular Pathology. Cancers (Basel). 10(4). pii: E100, 2018.
76. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 5(9):713–25, 2005.
77. Mullenders J, de Jongh E, Brousali A, et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proc Natl Acad Sci U S A. 116(10): 4567–4574, 2019.
78. Carramolino L, Lee BC, Zaballos A, et al. SA-1, nuclear protein encoded by one member of novel gene family: molecular cloning and detection in hemopoietic organs. Gene. 195(2):151–9, 1997.
79. Zhang N, Jiang Y, Mao Q, et al. Characterization of the intera ction between the cohesion subunits Rad21 and SA1/2. PLos One. 8(7):e69458, 2013.
80. Holzmann J, Fuchs J, Pichler P, Peters JM, Mechtler K. Lesson from the stoichiometry determination of the cohesion complex: a short protease mediated elution increases the recovery from cross-linked antibody-conjugated beads. J Proteome Res. 10(2): 780–9, 2011.
81. Benedatti L, Cerada M, Monteverde L, Desai N, Ciccarelli FD. Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1. Oncotarget. 8(23):37619–37632, 2017.
82. Kojic A, Cuadrado A, De Koninck M, et al. Distinct roles of cohesion-SA1 and cohesion-SA2 in 3D chromosome organization. Nat Struct Mol Biol. 25(6):496–504, 2018.
83. Wendt KS, Yoshida K, Itoh T, et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature. 451(7180):79–801, 2008.
84. Rubio ED, Reiss DJ, Welcsh PL, et al. CTCF physically links cohesion to chromatin. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8309–14.
85. Kagey MH, Newman JJ, Bilodeau S, et al. Mediator and cohesion connect gene expression and chromatin architecture. Nature. 467(7314):430–5, 2010.
86. Rollins RA, Morcillo P, Dorsett D. Nipped-B, a Drosophila homologue of chromosomal adherins, participates in acitivation by remote enhancers in the cut and Ultrabithorax genes. Genetics. 152(2):577–93, 1999.
87. Puhalla H, Kandioler D, Ludwig C, et al. p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res. 24(2C):1201–6, 2004.
88. Sjögren S, Inganäs M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sesquencing versus immunohistochemistry. J Natl Cancer Inst. 88(3-4):173–82, 1996.
89. Sanford T, Porten S, Meng MV. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 10(8):20137141, 2015.